Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · IEX Real-Time Price · USD
7.34
0.00 (0.00%)
At close: Mar 28, 2024, 4:00 PM
7.37
+0.03 (0.41%)
After-hours: Mar 28, 2024, 6:08 PM EDT
Fate Therapeutics Stock Forecast
Stock Price Forecast
The 12 analysts with 12-month price forecasts for Fate Therapeutics stock have an average target of 7.00, with a low estimate of 5.00 and a high estimate of 10. The average target predicts a decrease of -4.63% from the current stock price of 7.34.
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for FATE stock from 13 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
Rating | Oct '23 | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 3 | 3 | 3 | 3 | 2 |
Buy | 2 | 2 | 2 | 2 | 1 | 1 |
Hold | 13 | 13 | 13 | 13 | 9 | 9 |
Sell | 1 | 1 | 1 | 1 | 0 | 1 |
Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
Total | 19 | 20 | 20 | 20 | 13 | 13 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
B of A Securities | B of A Securities | Sell Maintains $2 → $6 | Sell | Maintains | $2 → $6 | -18.26% | Mar 28, 2024 |
HC Wainwright & Co. | HC Wainwright & Co. | Hold Reiterates $7 | Hold | Reiterates | $7 | -4.63% | Mar 19, 2024 |
Morgan Stanley | Morgan Stanley | Hold Maintains $3 → $7 | Hold | Maintains | $3 → $7 | -4.63% | Feb 27, 2024 |
BMO Capital | BMO Capital | Hold Maintains $6 → $7 | Hold | Maintains | $6 → $7 | -4.63% | Feb 27, 2024 |
Barclays | Barclays | Buy Maintains $6 → $10 | Buy | Maintains | $6 → $10 | +36.24% | Feb 27, 2024 |
Financial Forecast
Revenue This Year
6.60M
from 63.53M
Decreased by -89.61%
Revenue Next Year
4.62M
from 6.60M
Decreased by -30.03%
EPS This Year
-1.98
from -1.64
EPS Next Year
-1.79
from -1.98
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 26.3M | 31.5M | 21.0M | 53.6M | 260.7M |
Avg | 6.6M | 4.6M | 4.5M | 27.8M | 148.0M |
Low | n/a | n/a | n/a | n/a | 85.3M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -58.7% | 377.3% | 354.8% | 1,078.0% | 836.3% |
Avg | -89.6% | -30.0% | -1.5% | 512.5% | 431.5% |
Low | - | - | - | - | 206.2% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -1.47 | -0.93 | -1.43 | -0.93 | -0.83 |
Avg | -1.98 | -1.79 | -1.80 | -1.36 | -0.83 |
Low | -2.57 | -2.38 | -2.21 | -2.03 | -0.82 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | - |
Avg | - | - | - | - | - |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.